Mai H. Bui

Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer

Emily J. Faivre, Keith F. McDaniel, Daniel H. Albert et al. · Nature · 2020 · 404 citations

Life Sciences, Molecular Biology, Oncology +10

Micronutrient status and intake in omnivores, vegetarians and vegans in Switzerland

R. Schüpbach, Rita Wegmüller, C. Berguerand et al. · Zeitschrift für Ernährungswissenschaft · 2015 · 310 citations

Agriculture, Nutrition, Nutritional Sciences +12

Discovery of <i>N</i>-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor

Keith F. McDaniel, Le Wang, Todd Soltwedel et al. · Journal of Medicinal Chemistry · 2017 · 137 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Selective Chk1 inhibitors differentially sensitize p53‐deficient cancer cells to cancer therapeutics

Zehan Chen, Zhan Xiao, Wen‐Zhen Gu et al. · International Journal of Cancer · 2006 · 129 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain

George S. Sheppard, Le Wang, Steven D. Fidanze et al. · Journal of Medicinal Chemistry · 2020 · 121 citations · Full text

Medicine, Oncology, Pharmacology +12